The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Enhancing Anti-parasitic Drug Discovery With Metabolomics
Funder
National Health and Medical Research Council
Funding Amount
$483,402.00
Summary
Tropical diseases, such as malaria, infect millions of people each year, and drug resistance is emerging to current treatments. This research will improve our understanding of how current medicines work, and importantly, identify ways in which potential new drugs can kill malaria parasites.
Malaria And Infectious Diseases In The Asia-Pacific: Drugs, Vaccines And Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$210,873.00
Summary
Dr Karunajeewa is an expert in the treatment of malaria and other infectious diseases that have a major impact on the health of people living in developing countries of the tropical zone of the Asia-Pacific region. His ongoing research aims to develop better ways of diagnosing these infections, defining their relative importance in terms of overall burden of disease, finding optimal drug treatments and testing the effectiveness of new vaccines for their prevention.
Dissecting The Interactions Of Antimalarial Drugs With The Two Key Determinants Of Drug Resistance In The Malaria Parasite - The 'chloroquine Resistance Transporter' And The 'multidrug Resistance Transporter 1'
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
The malaria parasite is a single-celled organism which invades the red blood cells of its host. The aim of this fellowship is to study two proteins that are central to the parasite’s ability to evade the toxic effects of a number of drugs. The parasite's susceptibility to chloroquine, and other drugs, is altered by small changes in these proteins. This work will advance our understanding of the increasingly widespread phenomenon of antimalarial drug resistance, and of how it may be overcome.
A Transgenic Approach To Rationale Drug Design In Plasmodium Falciparum
Funder
National Health and Medical Research Council
Funding Amount
$420,872.00
Summary
Malaria is a disease caused by parasites of the genus Plasmodium. It is responsible for more than 2 million deaths per year predominately in Sub-Saharan Africa. Many of the currently used drugs to combat this disease are failing through drug resistance in the parasite population. New and novel drugs are urgently required. This project uses state of the art techniques to identify and validate new and novel targets within the parasite that can be used for rational drug design
The Hunt For New-generation Lipopeptide Antibiotics Targeting Gram-negative ‘Superbugs’
Funder
National Health and Medical Research Council
Funding Amount
$473,477.00
Summary
The dry antibiotic discovery and development pipeline, together with the increasing incidence of bacterial resistance in the clinic has been dubbed ‘the perfect storm’. This project involves the design, synthesis and preclinical evaluation of a new generation of polymyxin-like lipopeptides that have low nephrotoxicity and specifically target polymyxin-resistant Gram-negative ‘superbugs’.
LINEs Of Mutagenesis, Selection And Evolution In Ovarian Cancer And Chemoresistance
Funder
National Health and Medical Research Council
Funding Amount
$425,048.00
Summary
L1 elements are powerful mutagens encoded within the human genome that becomes active in epithelial tumours. I will define the broad effects of L1 elements on the evolution of chemoresistance, focusing on ovarian cancer as a model system. Ovarian cancer is characterised by a poor 5 year survival rate of ~40% with most tumours developing resistance. Understanding the impacts of L1 on this evolution will inform the development and selection of more effective treatments for ovarian cancer.
Improving On Nature: Diversifying Glycopeptide Antibiotics To Kill The Bacterial Pathogen Staphylococcus Aureus
Funder
National Health and Medical Research Council
Funding Amount
$476,728.00
Summary
Many bacteria have become resistant to existing antibiotics and we are badly in need of new antibiotics and strategies to combat them. My research centres on the class of antibiotics that includes the last resort therapy vancomycin. I aim to (1) develop novel ways to kill bacteria with these antibiotics and (2) understand and re-engineer the ways in which these antibiotics are produced. This will allow my team will develop new antibiotics to kill dangerous bacteria such as Staphylococcus aureus.
Studies On The Pathogenesis And Treatment Outcomes Of Chronic Viral Hepatitis
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
The global impact of hepatitis B and hepatitis C has recently been recognized by the World Health Organization. The Fellowship will support a research program that will use new technologies to answer a number of important questions concerning the pathogenesis of viral hepatitis B and C, interferon treatment response for HCV, and antiviral drug resistance. The outcomes of the research will be timely, clinically relevant, and of great interest to the international community. The ultimate goal is t ....The global impact of hepatitis B and hepatitis C has recently been recognized by the World Health Organization. The Fellowship will support a research program that will use new technologies to answer a number of important questions concerning the pathogenesis of viral hepatitis B and C, interferon treatment response for HCV, and antiviral drug resistance. The outcomes of the research will be timely, clinically relevant, and of great interest to the international community. The ultimate goal is to improve clinical outcomes for patients.Read moreRead less
Targeting Tumour-Stromal Interactions In Pancreatic Cancer
Funder
National Health and Medical Research Council
Funding Amount
$410,095.00
Summary
Pancreatic cancer claims five Australian lives every day and is one of the nations most lethal diseases. Despite aggressive treatment regimes, there has been no improvement in patient survival in the last decade. Evidence suggests that targeting cancer cells alone is not enough. The intense stromal reaction inhibits drug delivery and increases the aggressiveness of the tumours. Thus, depletion of the stroma or pancreatic stellate cells is a potential therapeutic target.
The extraordinary virulence of malaria parasites is in part due to their ability to export hundreds of proteins into their host cell to obtain nutrients and avoid the immune system. Recently the investigator has discovered the machinery that provides the gateway for these proteins to enter the host cell. She now aims to characterise this machinery and dissect its functional significance in vivo, so that strategies that block this crucial process can be developed to kill the parasite.